Search

Your search keyword '"Tang, Derek H."' showing total 36 results
Start Over Author "Tang, Derek H."
36 results on '"Tang, Derek H."'

21. Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor–methotrexate combination therapy versus triple therapy in rheumatoid arthritis

Author

Fleischmann, Roy, primary, Tongbram, Vanita, additional, van Vollenhoven, Ronald, additional, Tang, Derek H, additional, Chung, James, additional, Collier, David, additional, Urs, Shilpa, additional, Ndirangu, Kerigo, additional, Wells, George, additional, and Pope, Janet, additional

Published
2017
Full Text
View/download PDF

22. Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer.

Author

Princic, Nicole, Aizer, Ayal, Tang, Derek H., Smith, David M., Johnson, William, and Bardia, Aditya

Subjects
BREAST cancer, METASTATIC breast cancer
Abstract

Objective: To identify systemic treatment in the real-world following treatment with a cyclin-dependent kinase 4/6 inhibitor (CDKi) among post-menopausal women with hormone receptor positive, human epidermal growth factor receptor 2 Negative (HR+/HER2-) metastatic breast cancer (mBC).Methods: Post-menopausal women with HR+/HER2- mBC were identified from MarketScan claims databases between January 1, 2012 and October 31, 2017. Eligible mBC patients who received a CDKi-based line of therapy following metastasis diagnosis were selected. A line of therapy ended at the earlier of systemic therapy discontinuation, switch to new treatment, or censoring.Results: In total, 525 patients that received systemic therapy after a CDKi-based line were included (39.6% transitioned from use of a CDKi-based regimen in first line following metastasis diagnosis to any second line, and 60.4% shifted from a CDKi-based [second, third, or fourth line] to a subsequent line). Of post-CDKi second line regimens (n = 208), 38.0% were endocrine only, 35.6% were chemotherapy-based, 14.4% were everolimus-based, 9.6% were also CDKi-based line, and 2.4% were others. After adjusting for demographic and clinical characteristics, patients transitioning from a CDKi-based line to chemotherapy (vs others) had a trend of being more likely to have recurrent rapidly progressing disease, and were significantly less likely to have the prior CDKi-based line in combination with an AI (both p < .05).Conclusions: This population-based study suggests that rapidly progressing disease, metastatic site location, age, and endocrine therapy partner may be predictive of subsequent systemic therapy regimen selection after progression on a CDKi-based line therapy in patients with HR+/HER2- mBC. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

34. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis

Author

Sauer, Brian C., Teng, Chia-Chen, He, Tao, Leng, Jianwei, Lu, Chao-Chin, Walsh, Jessica A., Shah, Neel, Harrison, David J., Tang, Derek H., and Cannon, Grant W.

Abstract

AbstractObjective:To determine annual biologic drug and administration costs to the US Veterans Health Administration (VHA) per treated patient with rheumatoid arthritis (RA), psoriasis (PsO), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) who received abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab, or ustekinumab.Methods:Adults with at least one biologic claim between January 1, 2008 and December 31, 2011 were included. Evidence of enrollment in the VHA was required from 365 days before (pre-index) to 360 days after (post-index) the date of the first biologic claim (index date). Included patients had pre-index diagnoses of RA, PsO, PsA, and/or AS. Drug costs were from Federal Supply Schedule or ‘Big Four’ in November 2014. Administration costs were VHA fixed costs for infused ($169) and subcutaneous ($25) biologics.Results:Of the 20,465 patients in the analysis, 10,711 received etanercept, 7838 received adalimumab, and 1196 received infliximab as the index biologic. In these patients, across all uses studied, the VHA incurred greater annual cost per treated patient for infliximab ($18,066) compared with adalimumab ($16,523) and etanercept ($16,526). In the first year post-index, ∼80% of patients were either persistent on these index biologics or re-started these index biologics after a ≥45–day treatment gap. Other biologics comprised <5% of the study population, with sample sizes ranging from 3–374 patients each. Cost by indication for biologics used by >20 patients ranged from $15,056 (etanercept) to $17,050 (abatacept) for RA; $16,697 (adalimumab) to $33,163 (ustekinumab) for PsO; $15,035 (etanercept) to $20,465 (infliximab) for PsA; and $14,239 (etanercept) to $18,536 (infliximab) for AS.Limitations:The model was limited to the VHA. Results for biologics other than adalimumab, etanercept, and infliximab were difficult to interpret because of small sample sizes.Conclusions:Infliximab has higher cost to the VHA than adalimumab or etanercept.

Published
2016
Full Text
View/download PDF

35. Cost-effectiveness of biological agents used in ulcerative colitis.

Author

Le, Jeannie K., Tang, Derek H., Mollon, Le, and Armstrong, Edward P.

Subjects
ULCERATIVE colitis, COST effectiveness, BIOLOGICALS, MEDICAL care costs, HOSPITAL care, RESTORATIVE proctocolectomy, QUALITY of life, INFLIXIMAB
Abstract

Ulcerative colitis (UC) produces bloody diarrhoea, severe abdominal pain, and need for clinic visits, hospitalizations, and surgeries. UC results in reduced health-related quality of life for patients and large direct medical and indirect costs for health systems and employers. Patients with the most severe disease require the most medical services, and these patients have larger costs than patients with mild or moderate disease. Despite biological therapies being quite expensive, they are indicated for patients unresponsive to initial standard therapies. Future hospitalizations may be reduced by starting a biological treatment. Cost-effectiveness results vary between countries, health systems, and model designs. Since restorative proctocolectomy can be curative, this surgery dominates biological therapy by being both less costly and more effective when measuring health system costs and patient quality adjusted life years for 20 years. However the dose, duration, and effectiveness of biological treatments significantly impact estimates of their cost-effectiveness. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results